Mutual of America Capital Management LLC Has $22.89 Million Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Key Points

• Mutual of America Capital Management LLC has reduced its stake in Thermo Fisher Scientific Inc. by 2.8%, now owning 46,009 shares worth approximately $22.89 million.
• Analysts have mixed views on TMO, with price targets varying; Royal Bank of Canada reduced its target to $637, while Robert W. Baird increased its target to $567, indicating a consensus rating of "Moderate Buy."
• Thermo Fisher Scientific recently declared a quarterly dividend of $0.43 per share, with a dividend yield of 0.4%, reflecting a strong commitment to returning value to shareholders.

Mutual of America Capital Management LLC lessened its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 2.8% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 46,009 shares of the medical research company's stock after selling 1,339 shares during the period. Mutual of America Capital Management LLC's holdings in Thermo Fisher Scientific were worth $22,894,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the business. Revolve Wealth Partners LLC increased its position in Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after acquiring an additional 20 shares in the last quarter. Port Capital LLC increased its position in Thermo Fisher Scientific by 1.6% in the 4th quarter. Port Capital LLC now owns 1,385 shares of the medical research company's stock valued at $721,000 after acquiring an additional 22 shares in the last quarter. Clark Capital Management Group Inc. grew its position in shares of Thermo Fisher Scientific by 0.5% during the 4th quarter. Clark Capital Management Group Inc. now owns 4,445 shares of the medical research company's stock worth $2,312,000 after buying an additional 23 shares during the period. Monograph Wealth Advisors LLC grew its position in shares of Thermo Fisher Scientific by 0.3% during the 4th quarter. Monograph Wealth Advisors LLC now owns 8,656 shares of the medical research company's stock worth $4,507,000 after buying an additional 23 shares during the period. Finally, Intergy Private Wealth LLC grew its position in shares of Thermo Fisher Scientific by 5.8% during the 1st quarter. Intergy Private Wealth LLC now owns 419 shares of the medical research company's stock worth $208,000 after buying an additional 23 shares during the period. Institutional investors own 89.23% of the company's stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on the stock. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. HSBC reaffirmed a "hold" rating and issued a $510.00 price target on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Robert W. Baird lifted their price target on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a research note on Thursday, July 24th. Argus cut their price objective on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating on the stock in a research report on Tuesday, April 29th. Finally, Barclays upped their price target on shares of Thermo Fisher Scientific from $450.00 to $490.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 24th. Six investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $593.00.

Insider Buying and Selling

In other news, CEO Marc N. Casper sold 8,000 shares of the firm's stock in a transaction that occurred on Thursday, August 7th. The shares were sold at an average price of $454.45, for a total transaction of $3,635,600.00. Following the completion of the sale, the chief executive officer owned 115,174 shares of the company's stock, valued at $52,340,824.30. This trade represents a 6.49% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total transaction of $191,992.00. Following the sale, the executive vice president directly owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 18,400 shares of company stock valued at $8,345,792 in the last three months. Insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Price Performance

TMO traded up $6.60 on Friday, hitting $461.34. 1,689,914 shares of the stock were exchanged, compared to its average volume of 2,512,891. The firm has a market capitalization of $174.21 billion, a price-to-earnings ratio of 26.68, a PEG ratio of 2.40 and a beta of 0.74. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $627.88. The business has a 50-day moving average of $425.62 and a two-hundred day moving average of $464.94.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. The business had revenue of $10.86 billion during the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm's quarterly revenue was up 2.9% on a year-over-year basis. During the same quarter last year, the business earned $5.37 EPS. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio is currently 9.95%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.